Showing 6521-6530 of 7364 results for "".
- Allergan Acquires SkinMedicahttps://practicaldermatology.com/news/20121221-allergan_acquires_skinmedica/2459654/Allergan, Inc. completed the acquisition of SkinMedica, Inc. Under the terms of the agreement, which was first announced on November 16, 2012, Allergan paid approximately $350 million (subject to certain adjustments) for the business, which inclu
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in
- PreCision Dermatology Adds to Board of Directorshttps://practicaldermatology.com/news/20121211-precision_dermatology_adds_to_board_of_directors/2459660/PreCision Dermatology, Inc. appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 27 years. Most recently, as the Executive Vice Pr
- AD RescueWear Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/20121204-ad_rescuewear_receives_nea_seal_of_acceptance/2459662/The National Eczema Association Seal of Acceptance was awarded to AD RescueWear for its use by patients with eczema or severe sensitive skin conditions. AD RescueWear manufactures and sells ready-made, wet wrap therapy products for the treatment
- Wells Fargo Practice Finance Helps Practices Affected by Hurricane Sandyhttps://practicaldermatology.com/news/20121204-wells_fargo_practice_finance_helps_practices_affected_by_hurricane_sandy/2459663/As the northeastern United States recovers from the effects of Hurricane Sandy, Wells Fargo Practice Finance will donate disaster relief funds to the American Dental Association Foundation and other member organizations. Existin
- Court: Off-label Drug Promotion Is Protected Speechhttps://practicaldermatology.com/news/20121204-court_off-label_drug_promotion_is_protected_speech/2459665/The 2nd US Circuit Court of Appeals in New York voted 2-1 to overturn a pharmaceutical salesman's conviction for off-label drug marketing, citing violations against his free speech rights under the First Amendment. The ruling could threaten FDA rules that prevent the marketing of treatments for uses
- Tofacitinib Citrate Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121203-tofacitinib_citrate_approved_for_rheumatoid_arthritis/2459668/Pfizer Inc. received US FDA approval for XELJANZ (tofacitinib citrate) 5mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. XELJANZ
- New Data Show Stelara Effective for Psoriatic Arthritishttps://practicaldermatology.com/news/20121203-new_data_finds_stelara_effective_for_psoriatic_arthritis/2459669/Findings from the PSUMMIT II Phase 3 investigational study showed patients with active psoriatic arthritis receiving Stelara (ustekinumab, Jannsen) demonstrated significant improvements in signs and symptoms of the disease. Significantly more patie
- Jonah Shacknai Honored at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20121203-jonah_shacknai_honored_at_cosmetic_surgery_forum/2459670/Innovators in the field of cosmetic dermatology were honored this past weekend at Cosmetic Surgery Forum, a discussion-based CME symposium held in Las Vegas and now in its fourth year. Jonah Shacknai, Founder of Medicis, was the recipient of the Lifetime Achievement in Dermatology Award. On receivin
- Grants Awarded from National Rosacea Societyhttps://practicaldermatology.com/news/20121127-grants_awarded_from_national_rosacea_society/2459673/The National Rosacea Society (NRS) awarded funding to five new studies as part of its research grants program to increase knowledge and understanding of rosacea. Dr. Anna Di Nardo, associate professor of medicine at the University of California-San Diego, received $25,000 to study the role of mast c